text Therapeutics (US:CNTX) Globenewswire·2025-10-06 11:30Core Insights - Context Therapeutics Inc. is set to present two posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, focusing on their T cell engaging bispecific antibodies for solid tumors [1][2] Presentation Details - The first poster will detail a Phase 1 clinical trial of CT-95, a mesothelin x CD3 TCE, scheduled for presentation on November 8, 2025 [3] - The second poster will present preclinical data on CT-202, a Nectin-4 x CD3 TCE, to be showcased on November 7, 2025 [3] Product Information - CT-95 targets mesothelin, a protein overexpressed in approximately 30% of cancers, and aims to minimize the impact of shed MSLN that can interfere with treatment [4] - CT-202 targets Nectin-4, which is overexpressed in various solid tumors, and is designed to be preferentially active in the tumor microenvironment [5] Company Overview - Context Therapeutics is focused on developing T cell engaging bispecific antibodies, including CTIM-76, CT-95, and CT-202, and is headquartered in Philadelphia [6]